IP Verse

Translate Bio, Inc. opposition analysis

COMPANY ANALYSIS

Latest patents of Translate Bio, Inc. opposed by its competitors

Patent:
EP2858679
Grant Date:
Jun 5, 2024
Title:
Pulmonary Delivery Of Mrna To Non-Lung Target Cells
Oppositions:
1
Patent:
EP3501605
Grant Date:
Jun 28, 2023
Title:
Mrna Therapy For Argininosuccinate Synthetase Deficiency
Oppositions:
1
Patent:
EP2970456
Grant Date:
May 19, 2021
Title:
Methods And Compositions For Delivering Mrna Coded Antibodies
Oppositions:
4
Patent:
EP3336082
Grant Date:
Apr 15, 2020
Title:
Cleavable Lipids
Oppositions:
2
Patent:
EP3134506
Grant Date:
Aug 7, 2019
Title:
Methods For Purification Of Messenger Rna
Oppositions:
2
Patent:
EP3318248
Grant Date:
Apr 10, 2019
Title:
Delivery Of Mrna For The Augmentation Of Proteins And Enzymes In Human Genetic Diseases
Oppositions:
2
Patent:
EP3060303
Grant Date:
Nov 14, 2018
Title:
Mrna Therapy For Argininosuccinate Synthetase Deficiency
Oppositions:
1
Patent:
EP3122878
Grant Date:
Oct 24, 2018
Title:
Mrna Therapy For The Treatment Of Ocular Diseases
Oppositions:
1
Patent:
EP2506857
Grant Date:
Feb 14, 2018
Title:
Delivery Of Mrna For The Augmentation Of Proteins And Enzymes In Human Genetic Diseases
Oppositions:
2

Competitors of Translate Bio, Inc.

WITHERS & ROGERS LLP

BRADY, PAUL ANDREW

GLAXOSMITHKLINE BIOLOGICALS SA

Want to track Translate Bio, Inc.?

Feel free to send us a message here and we will get back to you